Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 239

1.

A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines.

Barkoff AM, Guiso N, Guillot S, Xing D, Markey K, Berbers G, Mertsola J, He Q.

J Immunol Methods. 2014 Jun;408:142-8. doi: 10.1016/j.jim.2014.06.001. Epub 2014 Jun 10.

PMID:
24925807
2.

International collaborative study: evaluation of proposed International Reference Reagent of pertussis antiserum (mouse) 97/642.

Gaines Das R, Xing D, Rigsby P, Newland P, Corbel M.

Biologicals. 2001 Jun;29(2):137-48.

PMID:
11580218
3.

Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.

Cherry JD, Heininger U, Richards DM, Storsaeter J, Gustafsson L, Ljungman M, Hallander HO.

Clin Vaccine Immunol. 2010 May;17(5):741-7. doi: 10.1128/CVI.00469-09. Epub 2010 Mar 24.

4.

Quantification of cell-associated and free antigens in Bordetella pertussis suspensions by antigen binding ELISA.

Westdijk J, van den Ijssel J, Thalen M, Beuvery C, Jiskoot W.

J Immunoassay. 1997 Aug;18(3):267-84.

PMID:
9257265
5.

Long-term immunogenicity of a single dose of acellular pertussis vaccine in paediatric health-care workers.

Littmann M, Hülsse C, Riffelmann M, Wirsing von König CH.

Vaccine. 2008 May 2;26(19):2344-9. doi: 10.1016/j.vaccine.2008.02.065. Epub 2008 Mar 19.

PMID:
18396360
6.

Construction of Bordetella pertussis strains with enhanced production of genetically-inactivated Pertussis Toxin and Pertactin by unmarked allelic exchange.

Buasri W, Impoolsup A, Boonchird C, Luengchaichawange A, Prompiboon P, Petre J, Panbangred W.

BMC Microbiol. 2012 Apr 23;12:61. doi: 10.1186/1471-2180-12-61.

7.

Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia.

Lam C, Octavia S, Ricafort L, Sintchenko V, Gilbert GL, Wood N, McIntyre P, Marshall H, Guiso N, Keil AD, Lawrence A, Robson J, Hogg G, Lan R.

Emerg Infect Dis. 2014 Apr;20(4):626-33. doi: 10.3201/eid2004.131478.

8.

Bordetella pertussis isolates in Finland: serotype and fimbrial expression.

Heikkinen E, Xing DK, Olander RM, Hytönen J, Viljanen MK, Mertsola J, He Q.

BMC Microbiol. 2008 Sep 25;8:162. doi: 10.1186/1471-2180-8-162.

10.

Acellular pertussis vaccines and the role of pertactin and fimbriae.

Poolman JT, Hallander HO.

Expert Rev Vaccines. 2007 Feb;6(1):47-56. Review.

PMID:
17280478
11.

Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.

Annunziato PW, Rothstein EP, Bernstein HH, Blatter MM, Reisinger KS, Pichichero ME.

Arch Pediatr Adolesc Med. 1994 May;148(5):503-7.

PMID:
8180641
12.

Efficacy of chemically cross-linked antigens for acellular pertussis vaccine.

Watanabe M, Nagai M, Funaishi K, Endoh M.

Vaccine. 2000 Dec 8;19(9-10):1199-203.

PMID:
11137257
13.

A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.

Cherry JD, Gornbein J, Heininger U, Stehr K.

Vaccine. 1998 Dec;16(20):1901-6.

PMID:
9796041
14.

Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens.

Macdonald-Fyall J, Xing D, Corbel M, Baillie S, Parton R, Coote J.

Vaccine. 2004 Oct 22;22(31-32):4270-81.

PMID:
15474718
15.

Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis.

Isacson J, Trollfors B, Hedvall G, Taranger J, Zackrisson G.

Scand J Infect Dis. 1995;27(3):273-7.

PMID:
8539553
16.

Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.

Ausiello CM, Urbani F, La Sala A, Lande R, Piscitelli A, Cassone A.

Dev Biol Stand. 1997;89:315-20.

PMID:
9272365
17.

Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines.

Boros CA, Hanlon M, Gold MS, Roberton DM.

Vaccine. 2001 May 14;19(25-26):3537-42.

PMID:
11348721
18.

Collaborative study on a Guinea pig serological method for the assay of acellular pertussis vaccines.

Winsnes R, Sesardic D, Daas A, Terao E, Behr-Gross ME.

Pharmeur Bio Sci Notes. 2009 Oct;2009(1):27-40.

PMID:
20144450
19.

Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model.

Marr N, Oliver DC, Laurent V, Poolman J, Denoël P, Fernandez RC.

Vaccine. 2008 Aug 12;26(34):4306-11. doi: 10.1016/j.vaccine.2008.06.017. Epub 2008 Jun 26.

PMID:
18582518
20.

Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.

Podda A, Carapella De Luca E, Titone L, Casadei AM, Cascio A, Bartalini M, Volpini G, Peppoloni S, Marsili I, Nencioni L, et al.

J Pediatr. 1993 Jul;123(1):81-4.

PMID:
8320630

Supplemental Content

Support Center